Phase I/II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Gene Engineered Lymphocytes Cotransduced With Genes Encoding IL-12 and Anti-NY ESO-1 TCR
- In prior trials we have shown that adoptive transfer of lymphocytes, transduced with a
T cell receptor (TCR) that recognizes the NY-ESO-1 antigen, can mediate regression of
metastatic cancer, though responses are often transient, and complete responses are
- Interleukin-12 (IL-12) is an important immunostimulatory cytokine. We have constructed
a retroviral vector that contains an inducible single chain IL-12 driven by an NFAT
responsive promoter which can be used to mediate transfer of this gene into anti-tumor
lymphocytes. This construct enables the secretion of IL-12 following stimulation of the
- Transduction of the IL-12 gene into mouse anti-tumor lymphocytes results in a profound
increase in the ability of these lymphocytes to mediate tumor regression following
administration to tumor bearing mice. These cells have a profound advantage in inducing
anti-tumor responses because very few cells are needed and there is no requirement for
the concomitant administration of interleukin-2 (IL-2) as is the case for conventional
cell transfer immunotherapies.
- Based on these studies we have now used a retrovirus that encodes an inducible human
single chain IL-12 driven by an NFAT responsive promoter and a retrovirus that encodes
an anti-NY-ESO-1 TCR to cotransduce autologous lymphocytes for the treatment of
patients with metastatic cancer that expresses the NY-ESO-1 antigen.
- To evaluate the safety of the administration of IL-12 and anti-NY-ESO-1 engineered
lymphocytes in patients receiving a non-myeloablative conditioning regimen.
- To determine if the administration of the transduced lymphocytes to patients following
a nonmyeloablative but lymphoid depleting preparative regimen will result in clinical
tumor regression in patients with metastatic cancer.
- To determine the in vivo survival of cotransduced gene-engineered cells.
Patients who are 18 years of age or older must have
- Metastatic cancer whose tumors express the ESO antigen;
- ECOG performance status 0 or 1;
- Autlogous lymphocytes will be cotransduced with retroviral vectors, encoding IL-12 and
anti- NY-ESO-1 TCR.
- Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen
consisting of cyclophosphamide and fludarabine followed by intravenous infusion of
IL-12/anti-ESO TCR gene-transduced lymphocytes.
- Patients will undergo complete evaluation of tumor with physical examination, CT of the
chest, abdomen and pelvis and clinical laboratory evaluation four to six weeks after
treatment. If the patient has SD or tumor shrinkage, repeat complete evaluations will
be performed every 1-3 months. After the first year, patients continuing to respond
will continue to be followed with this evaluation every 3-4 months until off study
criteria are met.
- The study will be conducted using a Phase I/II optimal design. The protocol will
proceed in a phase 1 dose escalation design. Initially, the protocol will enroll 1
patient in each of the first 3 dose cohorts unless that patient experiences a dose
limiting toxicity (DLT). Following cohort 3, all subsequent cohorts will proceed in a
phase 1 dose escalation design, with 5 cohorts of n=3. Should a single patient
experience a DLT due to the cell transfer at a particular dose level, additional
patients would be treated at that dose to confirm that no greater than 1/6 patients
have a DLT prior to proceeding to the next higher level. If a level with 2 or more DLTs
in 3-6 patients has been identified, three additional patients will be accrued at the
next-lowest dose, for a total of 6, in order to further characterize the safety of the
maximum tolerated dose (MTD) prior to starting the phase II portion. If a DLT occurs in
the first cohort, that cohort will be expanded to 6 patients. If 2 DLTs are encountered
in this cohort, the study will be terminated.
- Once the MTD has been determined, the study then will proceed to the phase II portion
using a phase II optimal design where initially 21 evaluable patients will be enrolled
in each of 2 cohorts. If 0 or 1 of the 21 patients experiences a clinical response,
then no further patients will be enrolled but if 2 or more of the first 21 evaluable
patients enrolled have a clinical response, then accrual will continue until a total of
41 evaluable patients have been enrolled.
- The objective will be to determine if the combination of lymphocyte depleting
chemotherapy, and IL-12/ESO TCR gene engineered lymphocytes is associated with a
complete response rate that can rule out 5% (p0=0.05) in favor of a modest 20% PR + CR
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the safety of the IL-12 and anti-NY-ESO-1 engineered PBL in patients receiving a non-myeloablative conditioning regimen, and to determine if patients with metastatic cancer will have clinical tumor regression following this regimen.
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|